UPDATE 1-Oculus skin and wound gel gets FDA approval

Wed Mar 10, 2010 8:34am EST

* U.S. Launch targeted for April 2010

* Shares up 61 percent in pre-market trade

March 10 (Reuters) - Oculus Innovative Sciences Inc (OCLS.O) said its Microcyn Skin and Wound HydroGel was approved by U.S. health regulators, sending its shares up 61 percent before the bell.

The company said the product, intended for management of wounds, including itch and pain relief associated with dermal irritation, sores, injuries and ulcers of dermal tissue, will be commercially available in April.

Shares of Oculus were trading at $2.89 before the bell. They had closed at $1.81 Tuesday on Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Bijoy Koyitty)


After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.